These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 29723705)

  • 1. Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination.
    Augustine R; Ashkenazi DL; Arzi RS; Zlobin V; Shofti R; Sosnik A
    Acta Biomater; 2018 Jul; 74():344-359. PubMed ID: 29723705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study.
    Antinori A; Meraviglia P; Monforte Ad; Castagna A; Mussini C; Bini T; Gianotti N; Rusconi S; Colella E; Airoldi G; Mancusi D; Termini R
    Drug Des Devel Ther; 2016; 10():1589-603. PubMed ID: 27226708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies.
    Midde NM; Gong Y; Cory TJ; Li J; Meibohm B; Li W; Kumar S
    Pharm Res; 2017 Sep; 34(9):1925-1933. PubMed ID: 28616684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
    Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
    Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel protease inhibitor-loaded Nanoparticle-in-Microparticle Delivery System leads to a dramatic improvement of the oral pharmacokinetics in dogs.
    Imperiale JC; Nejamkin P; Del Sole MJ; E Lanusse C; Sosnik A
    Biomaterials; 2015 Jan; 37():383-94. PubMed ID: 25453966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway.
    Taura M; Kariya R; Kudo E; Goto H; Iwawaki T; Amano M; Suico MA; Kai H; Mitsuya H; Okada S
    Free Radic Biol Med; 2013 Dec; 65():778-788. PubMed ID: 23973637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of the synthetic parameters of lipid polymer hybrid nanoparticles dual loaded with darunavir and ritonavir for the treatment of HIV.
    Elkateb H; Tatham LM; Cauldbeck H; Niezabitowska E; Owen A; Rannard S; McDonald T
    Int J Pharm; 2020 Oct; 588():119794. PubMed ID: 32828978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solid self-microemulsifying drug delivery system of ritonavir.
    Deshmukh A; Kulkarni S
    Drug Dev Ind Pharm; 2014 Apr; 40(4):477-87. PubMed ID: 23465049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solid self-nanoemulsifying drug delivery system (S-SNEDDS) of darunavir for improved dissolution and oral bioavailability: In vitro and in vivo evaluation.
    Inugala S; Eedara BB; Sunkavalli S; Dhurke R; Kandadi P; Jukanti R; Bandari S
    Eur J Pharm Sci; 2015 Jul; 74():1-10. PubMed ID: 25845633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
    Aoki M; Hayashi H; Yedidi RS; Martyr CD; Takamatsu Y; Aoki-Ogata H; Nakamura T; Nakata H; Das D; Yamagata Y; Ghosh AK; Mitsuya H
    J Virol; 2015 Nov; 90(5):2180-94. PubMed ID: 26581995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidomain drug delivery systems of β-casein micelles for the local oral co-administration of antiretroviral combinations.
    Singh Chauhan P; Abutbul Ionita I; Moshe Halamish H; Sosnik A; Danino D
    J Colloid Interface Sci; 2021 Jun; 592():156-166. PubMed ID: 33652169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Antiretroviral Therapy with Boosted Protease Inhibitors-Darunavir/Ritonavir or Darunavir/Cobicistat.
    Marin RC; Behl T; Negrut N; Bungau S
    Biomedicines; 2021 Mar; 9(3):. PubMed ID: 33803812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Darunavir concentration in PBMCs may be a better indicator of drug exposure in HIV patients.
    Nagano D; Araki T; Yanagisawa K; Ogawa Y; Gohda F; Uchiumi H; Handa H; Nakamura T; Yamamoto K
    Eur J Clin Pharmacol; 2018 Aug; 74(8):1055-1060. PubMed ID: 29721582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.
    Colbers A; Greupink R; Litjens C; Burger D; Russel FG
    Clin Pharmacokinet; 2016 Mar; 55(3):381-96. PubMed ID: 26369773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).
    Pellegrin I; Wittkop L; Joubert LM; Neau D; Bollens D; Bonarek M; Girard PM; Fleury H; Winters B; Saux MC; Pellegrin JL; Thiébaut R; Breilh D;
    Antivir Ther; 2008; 13(2):271-9. PubMed ID: 18505178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
    van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
    Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat
    Roberts O; Khoo S; Owen A; Siccardi M
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals.
    Jackson A; Else L; Higgs C; Karolia Z; Khoo S; Back D; Devitt E; Pozniak A; Boffito M
    HIV Clin Trials; 2018 Feb; 19(1):31-37. PubMed ID: 29189101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
    Pulido F; Arribas JR; Hill A; Van Delft Y; Moecklinghoff C
    Antivir Ther; 2011; 16(1):59-65. PubMed ID: 21311109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of unboosted darunavir in the setting of ritonavir intolerance: three case reports.
    Smith K; Gomes D; Nixon D; Fulco PP
    Int J Clin Pharmacol Ther; 2016 Jan; 54(1):52-7. PubMed ID: 26636419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.